DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES
申请人:Boehringer Ingelheim International GmbH
公开号:EP3560499A1
公开(公告)日:2019-10-30
The present invention relates to the use of a compound of general Formula (1),
optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, for the preparation of a pharmaceutical composition for the treatment of diseases characterized by abnormal cell proliferation in a human or non-human mammalian body by inhibition of polo like kinases as mitotic regulators.